Rich Pharmaceuticals, Inc., a biopharma company focused oncology therapies, has selected IND 2 Results, LLC, (I2R) of Atlanta GA, to serve as its CRO.

I2R will work on protocol development, medical writing, and regulatory consulting for Rich as it plans to move forward with clinical trials in Hodgkin’s Lymphoma (HL). I2R will also assist in preparing the protocol for submission to the FDA. 

I2R is also assisting the company in amending the Acute Myelocytic Leukemia (AML) protocol in preparation for the Submission Package to a major U.S. clinical site, will prepare submission packages for the clinical site’s Institutional Review Board (IRB). Rich Pharmaceuticals plans to conduct a study for the treatment of AML in refractory patients in Phase I/II trial. AML is a cancer of the myeloid line of blood cells, characterized by the rapid growth of abnormal white blood cells that build up in the bone marrow and interfere with the production of normal blood cells.

 “I2R has a strong track record of success in conducting complicated clinical trials. Its multi-disciplinary team of experienced clinical trial professionals will work with Rich Pharmaceuticals as we move forward with our innovative treatment for lymphoma and leukemia,” said Ben Chang, Rich Pharmaceuticals chief executive officer. “We believe that getting a talented CRO team on board is an important step for our future.”